More than 75,000 Australians live with Geographic Atrophy (GA), an advanced form of Age-Related Macular Degeneration and one of the leading causes of blindness worldwide.
GA is a progressive eye disease that leads to central vision loss. While there are no current treatments to restore vision, we at Vision Australia support therapies that slow the progression of GA and reduce its functional impacts. Early detection and treatment can significantly lessen the need for further support.
A new treatment option is now available
The recent approval of a new treatment by the Therapeutic Goods Administration (TGA), developed by Apellis Pharmaceuticals, offers a new opportunity for managing GA. This drug has the potential to slow disease progression and help preserve vision for a longer period.
By slowing vision loss, this treatment can allow someone living with GA to maintain their independence and continue everyday activities like reading and navigating their environment.
While it does not restore lost vision, the new drug and its ability to delay progression could have a meaningful impact on daily life.
The impacts of GA
Living with GA can come with many challenges, but understanding its impact can help people prepare and seek the right support.
Did you know?
- 66% of patients with GA become blind or visually impaired1
- GA-related vision loss significantly affects quality of life and independence. For example, 67% of patients may lose their ability to drive within 1.6 years after diagnosis2
- 63% of patients with GA report difficulty with everyday tasks and leisure3.
These statistics, while overwhelming, reinforce the importance of early detection, intervention and support.
Other helpful strategies
There are many ways to adapt and maintain independence while living with GA. These can include:
- Assistive technology: Screen readers, magnifiers, and smart home devices can improve accessibility.
- Mobility and orientation training: White cane training or using a Seeing Eye Dog can help with navigation.
- Home modifications: Improved lighting, high-contrast markings and tactile cues can enhance safety.
- Emotional support: Counselling, peer support groups and community programs can provide reassurance and connection.
For more information
Vision Australia remains committed to supporting research and advancements in the prevention and treatment of vision loss. We encourage those affected by GA to speak with their eye health professional to learn more about available treatments and if this new drug is the right solution for them.
To read the full announcement about the newly TGA approved pharmaceutical, you can visit the Appelis website.